Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases

2018 ◽  
Author(s):  
Toshihiro Masuda ◽  
Taisuke Akamatsu ◽  
Eiji Nakatani ◽  
Kanami Tamura ◽  
Shingo Takahashi ◽  
...  
Keyword(s):  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Respiratory Diseases ◽  
The Elderly ◽  
Polysaccharide Vaccine ◽  
Pneumococcal Polysaccharide Vaccine ◽  
Chronic Respiratory Diseases

scholarly journals Effectiveness of a 23-valent pneumococcal polysaccharide vaccine for the prevention of pneumococcal pneumonia in the elderly with chronic respiratory diseases: a case–control study of a single center

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Toshihiro Masuda ◽  
Eiji Nakatani ◽  
Toshihiro Shirai ◽  
Taisuke Akamatsu ◽  
Kanami Tamura ◽  
...  
Keyword(s):  
Odds Ratio ◽  
Respiratory Diseases ◽  
Pneumococcal Pneumonia ◽  
Case Control Study ◽  
The Elderly ◽  
Case Control ◽  
Polysaccharide Vaccine ◽  
Pneumococcal Polysaccharide Vaccine ◽  
Chronic Respiratory Diseases ◽  
Control Study

Abstract Background The effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in preventing pneumococcal pneumonia has been controversial. Methods To evaluate the effectiveness of the PPSV23 in elderly outpatients with chronic respiratory diseases, we carried out a case–control study, including 4128 outpatients aged ≥ 65 years, in the respiratory department. Results There were 320 vaccinated patients, of which 164 were diagnosed with pneumococcal pneumonia. The adjusted odds ratio was 0.39 (95% confidence interval (CI), 0.17 to 0.89). In the subsets consisting of age groups ≥ 70 and ≥ 75 years, the adjusted odds ratio (95% CI) was respectively 0.16 (0.04 to 0.67) and 0.15 (0.02 to 1.12). Conclusion This real-world study suggests that PPSV23 can be useful in preventing pneumococcal pneumonia in the elderly with chronic respiratory diseases.

scholarly journals Effectiveness of a 23-valent Pneumococcal Polysaccharide Vaccine for the Prevention of Pneumococcal Pneumonia in the Elderly with Chronic Respiratory Diseases: A Case-control Study of a Single Center

2021 ◽  
Author(s):  
Toshihiro Masuda ◽  
Eiji Nakatani ◽  
Toshihiro Shirai ◽  
Taisuke Akamatsu ◽  
Kanami Tamura ◽  
...  
Keyword(s):  
Odds Ratio ◽  
Respiratory Diseases ◽  
Pneumococcal Pneumonia ◽  
Case Control Study ◽  
The Elderly ◽  
Case Control ◽  
Polysaccharide Vaccine ◽  
Pneumococcal Polysaccharide Vaccine ◽  
Chronic Respiratory Diseases ◽  
Control Study

Abstract Background: The effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in preventing non-invasive pneumococcal pneumonia (non-IPD) has been controversial.Methods: To evaluate the effectiveness of the PPSV23 in elderly outpatients with chronic respiratory diseases, we carried out a case-control study, including 4128 outpatients aged ≥ 65 years, in the respiratory department.Results: There were 320 vaccinated patients, of which 164 were diagnosed with pneumococcal pneumonia. The adjusted odds ratio was 0.39 (95 % confidence interval (CI), 0.17 to 0.89). In the subsets consisting of age groups ≥ 70 and ≥ 75 years, the adjusted odds ratio (95 % CI) was respectively 0.16 (0.04 to 0.67) and 0.15 (0.02 to 1.12).Conclusion: This real-world study suggests that PPSV23 is effective in preventing pneumococcal pneumonia in the elderly with chronic respiratory diseases and in the older population (age ≥ 75 years).

Sign in / Sign up

Export Citation Format

Share Document